Compare ResMed Inc. (RMD) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Symbotic Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.78B), while Symbotic Inc trades at $42.61 (market cap $5.62B). The key difference: ResMed Inc. is far larger — about 5.7× Symbotic Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Symbotic Inc for 23 Days on average.
| RMD | SYM | |
|---|---|---|
Market Cap | $31.78B | $5.62B |
Volume | 1,128,382 | 1,339,679 |
Sector | Health | Industrials |
52-Week High | $277.88 | $87.30 |
52-Week Low | $182.82 | $38.22 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | $31.14B | $3.88B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth potential with a $22.5 billion backlog but faces profitability challenges with negative net income of -$16.94 million in 2025. Analyst consensus is positive with a $60.33 price target, though recent earnings misses and customer concentration risk remain concerns.
SYM presents a growth opportunity in warehouse automation with significant backlog and expanding market demand, but investors must weigh high valuation multiples against current profitability issues and execution risks. The stock's upside depends on successful margin expansion and diversification beyond its major customer relationship.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
